Dolaf- an international multicenter phase 2 trial of durvalumab (medi4736) plus olaparib plus fulvestrant in metastatic or locally advanced er-positive, her2-negative breast cancer patients selected using criteria that predict sensitivity to olaparib (UCB

Affiliation auteurs!!!! Error affiliation !!!!
TitreDolaf- an international multicenter phase 2 trial of durvalumab (medi4736) plus olaparib plus fulvestrant in metastatic or locally advanced er-positive, her2-negative breast cancer patients selected using criteria that predict sensitivity to olaparib (UCB
Type de publicationJournal Article
Year of Publication2021
AuteursGuiu S, Balmana J, Roca L, Goncalves A, Mailliez A, Bigot F, Bachelot T, Dalenc F, Dohollou N, Genet D, Desmoulins I, Chakiba C, Delaloge S, Martineau G, Haddad V, Follana P
JournalCANCER RESEARCH
Volume81
Date PublishedFEB
Type of ArticleMeeting Abstract
ISSN0008-5472